Explore more publications!
Penn STEM Times
Submit Press Release

Penn STEM Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Penn STEM Times.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 19, 2025

Quantexa ได้รับการจัดอันดับเป็นผู้นำหมวดหมู่ในรายงานโซลูชัน AML Transaction Monitoring และ KYC ปี 2025 ของ Chartis Research
November 19, 2025

Quantexa ได้รับการจัดอันดับเป็นผู้นำหมวดหมู่ในรายงานโซลูชัน AML Transaction Monitoring และ KYC ปี 2025 ของ Chartis Research

Indeterminate GlobeNewswire
Quantexa als Kategorieführer in den Berichten „AML Transaction Monitoring“ und „KYC Solutions“ von Chartis Research 2025 ausgezeichnet
November 19, 2025

Quantexa als Kategorieführer in den Berichten „AML Transaction Monitoring“ und „KYC Solutions“ von Chartis Research 2025 ausgezeichnet

Indeterminate GlobeNewswire
Quantexa נבחרה כמובילת קטגוריה בדו"חות AML Transaction Monitoring ו- KYC Solutions ל- 2025 של Chartis Research
November 19, 2025

Quantexa נבחרה כמובילת קטגוריה בדו"חות AML Transaction Monitoring ו- KYC Solutions ל- 2025 של Chartis Research

Indeterminate GlobeNewswire
Quantexa, Chartis Research 2025 AML 거래 모니터링 및 KYC 솔루션 보고서에서 카테고리 리더로 선정
November 19, 2025

Quantexa, Chartis Research 2025 AML 거래 모니터링 및 KYC 솔루션 보고서에서 카테고리 리더로 선정

Indeterminate GlobeNewswire
Quantexa Dinobatkan sebagai Peneraju Kategori dalam Laporan Penyelesaian Pemantauan Transaksi AML dan KYC Chartis Research 2025
November 19, 2025

Quantexa Dinobatkan sebagai Peneraju Kategori dalam Laporan Penyelesaian Pemantauan Transaksi AML dan KYC Chartis Research 2025

Indeterminate GlobeNewswire
Quantexa được Chartis Research vinh danh là Công ty Dẫn đầu danh mục trong Báo cáo Giải pháp Giám sát Giao dịch AML và KYC năm 2025
November 19, 2025

Quantexa được Chartis Research vinh danh là Công ty Dẫn đầu danh mục trong Báo cáo Giải pháp Giám sát Giao dịch AML và KYC năm 2025

Indeterminate GlobeNewswire
Arch Biopartners Closes Non-Brokered Private Placement
November 19, 2025

Arch Biopartners Closes Non-Brokered Private Placement

Indeterminate GlobeNewswire
NVIDIA Announces Financial Results for Third Quarter Fiscal 2026
November 19, 2025

NVIDIA Announces Financial Results for Third Quarter Fiscal 2026

Indeterminate GlobeNewswire
PRIMEENERGY RESOURCES CORPORATION (PNRG) ANNOUNCES THIRD QUARTER RESULTS
November 19, 2025

PRIMEENERGY RESOURCES CORPORATION (PNRG) ANNOUNCES THIRD QUARTER RESULTS

Indeterminate GlobeNewswire
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
November 19, 2025

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Indeterminate GlobeNewswire
Cerence Beats Upper End of Guidance, Delivering Strong Fourth Quarter and Fiscal Year 2025 Results; Projects 8% Growth in Core Technology Business in FY26
November 19, 2025

Cerence Beats Upper End of Guidance, Delivering Strong Fourth Quarter and Fiscal Year 2025 Results; Projects 8% Growth in Core Technology Business in FY26

Indeterminate GlobeNewswire
ODDITY Tech Reports Record Third Quarter Results, Raises Full Year Outlook
November 19, 2025

ODDITY Tech Reports Record Third Quarter Results, Raises Full Year Outlook

Indeterminate GlobeNewswire
ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2025
November 19, 2025

ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2025

Indeterminate GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 19, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
SHIZA Set to Launch $MOAA Token, ‘The Mother of All Agents’ on Creator.Bid, Empowering True Ownership of AI
November 19, 2025

SHIZA Set to Launch $MOAA Token, ‘The Mother of All Agents’ on Creator.Bid, Empowering True Ownership of AI

Indeterminate GlobeNewswire
Infoblox Launches Predictive DNS-Based Threat Protection Solution on AWS
November 19, 2025

Infoblox Launches Predictive DNS-Based Threat Protection Solution on AWS

Indeterminate GlobeNewswire
First Look at Roche/Genentech’s Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights
November 19, 2025

First Look at Roche/Genentech’s Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights

Indeterminate GlobeNewswire
Bitcoin Falls Below $90,000 Again, Ethereum Drops Below $3,000: How Should We Position Ourselves?
November 19, 2025

Bitcoin Falls Below $90,000 Again, Ethereum Drops Below $3,000: How Should We Position Ourselves?

Indeterminate GlobeNewswire
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
November 19, 2025

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Indeterminate GlobeNewswire
Michaels, Ross & Cole Announces m-Power AI Update: Bring AI to the Systems You Already Own
November 19, 2025

Michaels, Ross & Cole Announces m-Power AI Update: Bring AI to the Systems You Already Own

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions